PARD6A and prostate cancer: The earlier studies showed that the Par6α-contained complexes facilitated EMT in NSCLC [55, 56], while Zhang et al. suggested that the complex, composed of Par6α, Par3 and aPKC, had the opposite effects on prostate cancer cells [57].